Prevalence and risk factors of virological failure among children on antiretroviral therapy
| dc.contributor.author | Owusu, Michael | |
| dc.contributor.author | Mensah, Michael | |
| dc.contributor.author | Enimil, Anthony | |
| dc.contributor.author | Mutocheluh, MOhammed | |
| dc.contributor.orcid | 0000-0001-5066-150X | |
| dc.contributor.orcid | 0000-0001-6521-3400 | |
| dc.date.accessioned | 2024-02-21T11:02:45Z | |
| dc.date.available | 2024-02-21T11:02:45Z | |
| dc.date.issued | 2017 | |
| dc.description | This is an article published in BMJ Glob Health 2017;2(Suppl 2):A1–A67 | |
| dc.description.abstract | An unprecedented global effort at scaling up universal access to antiretroviral therapy has decreased the progression of HIV. However, due to challenges with supplies and adherence to intermittent antiretroviral therapy (ART) for mothers, infants continue to be infected, some with resistant viruses. Exposure to these resistant strains leads to non responsiveness to therapy resulting in virological failure. Children are more vulnerable to HIV drug resistance because of their life long treatment, the possible selection of resistant strains as a result of prophylaxis for mothers with HIV enrolled in PMTCT. The objective of the study was to determine the prevalence and risk factors of virological resistance among HIV-1-positive children on antiretroviral therapy. | |
| dc.description.sponsorship | KNUST | |
| dc.identifier.citation | BMJ Glob Health 2017;2(Suppl 2):A1–A67 | |
| dc.identifier.uri | https://ir.knust.edu.gh/handle/123456789/15512 | |
| dc.language.iso | en | |
| dc.publisher | BMG Glob Health | |
| dc.title | Prevalence and risk factors of virological failure among children on antiretroviral therapy | |
| dc.type | Article |